Subscribe to our newsletter

Committed To Patients And Science

Takeda is committed to developing innovative medicines and new approaches to treatment that are accessible to as many people as possible, regardless of where they live or their ability to pay

Takeda mission is to strive towards better health for people worldwide, including in our region. In fiscal year 2022, the company’s R&D investment totalled $4.8 billion, and it doesn’t end there. This is a conversation about Takeda’s plans and its launching and registering of new medicines.

Everything at Takeda begins with the question of how you can do more for the patient. What does that mean specifically? That you strive to ensure that your innovative medicines and new approaches to treatment are available to as many people as possible?

― At Takeda, our mission is to strive towards better health for people worldwide by leading innovation in medicine. This means that we are constantly asking ourselves how we can do more for the patient, and this is reflected in everything we do.

We are committed to developing innovative medicines and new approaches to treatment that are accessible to as many people as possible, regardless of where they live or their ability to pay. We believe that everyone deserves access to the best possible healthcare and are dedicated to making that a reality.

Your innovations, which are the result of research and development globally, impact the lives of patients worldwide by converting scientific findings into life-changing medicines. What are the latest innovative solutions Takeda has brought to the countries for which you are responsible?

― Takeda is building one of the most exciting and diverse pipelines in the industry, with approximately 40 new molecular entities, 50% of which are with orphan drug designation. Our R&D investment was $4.8 billion in fiscal year 2022. We are committed to bringing innovative solutions to patients in Croatia, Slovenia, Bosnia and Herzegovina, and around the world.

One of our latest innovations is darvadstrocel, Europe’s first allogeneic stem cell therapy that represents a new treatment option for patients suffering from Crohn’s perianal fistula

One of our latest innovations is darvadstrocel, Europe’s first allogeneic stem cell therapy that represents a new treatment option for patients suffering from Crohn’s perianal fistula who do not respond to currently available therapies and may be subject to numerous invasive surgeries. Launching this medicine has been transformative for patients and we are proud to be able to offer it in our countries.

How does the process of registering a prescription drug look within the EU, compared to other countries? How long does it take for a medication to progress from registration to being made available to the intended patient?

― The process of registering a prescription drug within the EU is a rigorous and complex process that involves multiple stages of testing and evaluation. The European Medicines Agency (EMA) is responsible for evaluating the safety, efficacy and quality of new medicines before they can be approved for use in the EU. This process can take several years, depending on the complexity of the drug and the amount of data that needs to be reviewed. Once a drug is approved by the EMA, it can be made available to patients in all EU member states. The process of getting a drug to market in non- EU countries can vary depending on the regulatory requirements of each country, but it generally occures about a year after EU approval. In order to bridge this registration and subsequent reimbursement gap, we often create various free of charge early access programmes to make the medicine available to patients in Bosnia and Herzegovina.

Must Read

Albania Awards 283.9 MW in Solar Power Auction, Lowest Bid at EUR 39.7 per MWh

The auction saw bids exceeding the available quota of 300 MW, with the lowest offer coming in at EUR 39.7 per MWh, significantly below...

Živko Mukaetov, CEO/MB President of Alkaloid AD Skopje

Our Brands are Part of People’s Lives

Comment

Let’s Celebrate Opportunities